High dose Losartan and ACE gene polymorphism in IgA nephritis

Genomic Medicine

Volumn 2, Issue 3-4, 2008, Pages 83-91

  Woo, Keng Thye ^a   Chan, Choong Meng ^a   Choong, Hui Lin ^a   Tan, Han Kim ^a   Foo, Marjorie ^a   Lee, Evan J C ^b   Tan, Chorh Chuan ^b   Lee, Grace S L ^c   Tan, Seng Hoe ^d   Vathsala, A ^a   Lim, Cheng Hong ^a   Chiang, Gilbert S C ^a   Fook Chong, Stephanie ^a   Yi, Zhao ^a   Tan, H B ^a   Wong, Kok Seng ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c GLENEAGLES HOSPITAL   (Singapore)

^d TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

ACE Gene polymorphism; Angiotensin receptor blockers; Glomerular filtration rate; Proteinuria; Renal failure; Treatment

Indexed keywords

EID: 68049126389     PISSN: 18717934     EISSN: 18717942     Source Type: Journal    
DOI: 10.1007/s11568-009-9030-8     Document Type: Article

References (19)

1. S Andersen L Tarnow F Cambien P Rossing TR Juhl J Deinum HH Parving 2002 Renoprotective effects of Losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int 62 192 198 10.1046/j.1523-1755.2002. 00410.x
2. P Aranda J Segura LM Ruilope FJ Aranda MA Frutos V Lopez E Lopez de Novales 2005 Long term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies Am J Kidney Dis 46 1074 1079 10.1053/j.ajkd.2005.08.034
3. JC Chan NM Wat WY So KS Lam CT Chua KS Wong Z Morad TZ Dickson D Hille 2004 Reduction in Endpoints in NIDDM with angiotensin II antagonist Losartan study investigators. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: an Asian perspective from the RENAAL study Diabetes Care 27 874 879 10.2337/diacare.27.4.874
4. JJ Dillon 2004 Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy Semin Nephrol 24 218 224 10.1016/j.semnephrol.2004.01.003
5. SY Han YJ Kwon SK Jo JH Shin DR Cha WY Cho HJ Pyo HK Kim 2000 ACE gene polymorphism and renal responsiveness to ACE inhibitors in IgA nephropathy patients Korean J Intern Med 15 1 13 18
6. PN Harden C Geddes PA Rowe JH Ilroy M Boulton-Jones RS Rodger 1995 Polymorphisms in angiotensin-converting enzyme gene and progression of IgA nephropathy Lancet 345 1540 1542 10.1016/S0140-6736(95)91088-3
7. NK Hollenberg HH Parving G Viberti G Remuzzi S Ritter S Zelenkofske A Kandra W Daley R Rocha 2007 Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus J Hypertens 25 1921 1926 10.1097/HJH.0b013e328277596e
8. TE Hunley BA Julian JA Phillips L Summar H Yoshida RG Horn NJ Brown A Fogo I Ichikawa 1996 Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy Kidney Int 49 571 577 10.1038/ki.1996.81 (Pubitemid 26051837)
9. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T (2008) Combination treatment of angiotensin II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial
10. DP Ng BC Tai D Koh KW Tan KS Chia 2005 Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14, 727 subjects Diabetologia 48 1008 1016 10.1007/s00125-005-1726-2
11. H Nonoguchi Y Nakayama T Shiigai T Inoue H Inoue Y Kohda Y Honda K Tomita 2007 Low responders to angiotensin II receptor blockers and genetic polymorphism in angiotensin-converting enzyme Clin Nephrol 68 209 215 (Pubitemid 47527440)
12. K Rossing KJ Schjoedt BR Jensen F Boomsma HH Parving 2005 Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria Kidney Int 68 1190 1198 10.1111/j.1523-1755.2005. 00511.x
13. N Seki N Hashimoto Y Suzuki K Yagui Y Saito 2006 Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy Diabetes Res Clin Pract 72 135 141 10.1016/j.diabres.2005.09.015
14. S Suzuki Y Suzuki Y Kobayashi T Harada T Kawamura 2000 Insertion/deletion polymorphism in ACE gene is not associated with renal progression in Japanese patients with IgA nephropathy Am J Kidney Dis 35 896 903 10.1016/S0272-6386(00) 70261-7 (Pubitemid 30238203)
15. LJ Vleming C Van Kooten M Van Dijik D Amj Hollander RGJ Westerndrop LA van Es 1998 The D-allele of the ACE gene polymorphism predicts a stronger antiproteinuric response to ACE inhibitors Nephrology 4 143 149 10.1046/j.1440-1797.1998.d01-30.x (Pubitemid 28364550)
16. KT Woo YK Lau KS Wong 2000 ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis Kidney Int 58 2485 2491 10.1046/j.1523-1755.2000.00432.x
17. KT Woo YK Lau CM Chan 2005 ATRA therapy restores normal renal function and renal reserve and prevents renal failure Ann Acad Med Singapore 34 52 59 (Pubitemid 40379973)
18. KT Woo YK Lau CM Chan KS Wong 2008 Angiotensin converting enzyme inhibitor versus angiotensin 2 receptor antagonist therapy and the influence of angiotensin converting enzyme gene polymorphism in IgA nephritis Ann Acad Med Singapore 37 5 372 377
19. D Yong WQ Qing L Hua JJ Kan CJ Xi QQ Jin SH Chao 2006 Association of angiotensin I-converting enzyme gene insertion/deletion polymorphism and IgA nephropathy: a meta-analysis Am J Nephrol 26 5 511 518 10.1159/000097367